124 filings
Page 6 of 7
8-K/A
143x5 hzhp
17 May 19
Departure of Directors or Certain Officers
4:12pm
8-K/A
o52ao7x
13 May 19
Financial Statements and Exhibits
4:58pm
8-K
io5pa
15 Apr 19
X4 Pharmaceuticals Prices $85.8 Million Public Offering of Common Stock and Class A Warrants
4:41pm
8-K
vsoz 973sa
12 Apr 19
X4 Pharmaceuticals Announces Proposed Public Offering of Common Stock and Class A Warrants
6:08am
8-K
v12ywjr zjl
11 Apr 19
Other Events
4:00pm
8-K/A
qqu18
3 Apr 19
Index to Consolidated Financial Statements
12:00am
8-K
828yk
2 Apr 19
Departure of Directors or Certain Officers
8:37am
8-K
o0z0p3 95d
1 Apr 19
Regulation FD Disclosure
9:26am
8-K
lhszqgcwmye7rf
13 Mar 19
X4 Pharmaceuticals Completes Merger with Arsanis
5:28pm
8-K
aydtbub7y tibm
8 Mar 19
Entry into a Material Definitive Agreement
5:14pm
8-K
3l9r4
1 Mar 19
Termination of a Material Definitive Agreement
4:38pm
8-K
lrvtu7t
8 Feb 19
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
4:27pm
8-K
musy2j z1chcxvafwx
16 Jan 19
Departure of Directors or Certain Officers
5:01pm
8-K
jx8mzf ytoay
20 Dec 18
Entry into a Material Definitive Agreement
5:09pm
8-K
loqtr2d3
27 Nov 18
Other Events
5:22pm
8-K
c6vresfu6191oq6x1w
27 Nov 18
Entry into a Material Definitive Agreement
7:10am
8-K
c7tzm11 pp0frr
9 Nov 18
Arsanis Reports Financial Results for Third Quarter 2018
8:15am
8-K
xwefvq
13 Aug 18
Arsanis Reports Financial Results for Second Quarter 2018
8:18am
8-K
aas wb1bk379lucora1n
28 Jun 18
Arsanis Provides Update Following Completion of Planned Interim Analysis
7:11am
8-K
u6lr7hat3tr8sc
12 Jun 18
Entry into a Material Definitive Agreement
12:00am